AVTX Stock Overview
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases.
Avalo Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.25|
|52 Week High||US$23.82|
|52 Week Low||US$2.42|
|1 Month Change||-21.05%|
|3 Month Change||7.58%|
|1 Year Change||-77.21%|
|3 Year Change||-90.06%|
|5 Year Change||-77.09%|
|Change since IPO||-89.06%|
Recent News & Updates
|AVTX||US Biotechs||US Market|
Return vs Industry: AVTX underperformed the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: AVTX underperformed the US Market which returned -21.2% over the past year.
|AVTX Average Weekly Movement||11.4%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: AVTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: AVTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn’s disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still’s disease, including adult-onset still’s disease and systemic juvenile idiopathic arthritis.
Avalo Therapeutics, Inc. Fundamentals Summary
|AVTX fundamental statistics|
Is AVTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AVTX income statement (TTM)|
|Cost of Revenue||US$29.46m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-5.41|
|Net Profit Margin||-293.41%|
How did AVTX perform over the long term?See historical performance and comparison